Hygeia Healthcare (6078) H1 2026 earnings summary

Executive summary

• Recorded 2.3 million patient visits in H1 2026, up 4.1% year-over-year; outpatient visits rose 4.5% and surgeries increased 8.2%.

• Patient satisfaction reached 99.3%, up 1.9 percentage points year-over-year.

• Expanded hospital network to 17 oncology-focused hospitals across 13 cities in 8 provinces, with one new Class III hospital under construction.

• Continued focus on oncology, complex, and emergency care, with 38 key clinical specialties and 118 high-level medical talents.

• Revenue for H1 2026 was RMB1,961.0 million, down 1.4% year-over-year, while net profit rose 4.7% to RMB257.4 million and non-IFRS adjusted net profit increased 1.5% to RMB266.5 million.

Financial highlights

• Revenue: RMB1,961.0 million (-1.4% YoY); Net profit: RMB257.4 million (+4.7% YoY); Non-IFRS adjusted net profit: RMB266.5 million (+1.5% YoY).

• Gross profit: RMB537.2 million; gross margin improved by 0.8 percentage points to 27.4%.

• Net cash from operating activities was RMB458.7 million, up 0.7%; free cash flow increased 38.5% to RMB296.3 million.

• Basic EPS was RMB0.42, up 5.0% year-over-year.

• Interest-bearing liabilities decreased by 7.4% to RMB2,256.4 million from December 31, 2025.

Outlook and guidance

• Plans to allocate RMB500 million annually for shareholder returns via share repurchases and/or dividends through 2028; Board approved a three-year, RMB1.5 billion shareholder return plan.

• Focus on expanding international medical services and non-insurance-covered offerings.

• Will pursue selective, high-quality M&A opportunities and further enhance ESG practices.

• Anticipates further improvement in free cash flow as capital expenditures decline.